165 related articles for article (PubMed ID: 26231307)
1. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
3. Pimasertib-associated ophthalmological adverse events.
van Dijk EHC; Kruit WHJ; Jager MJ; Luyten GPM; Vingerling JR; Boon CJF
Acta Ophthalmol; 2018 Nov; 96(7):712-718. PubMed ID: 29338133
[TBL] [Abstract][Full Text] [Related]
4. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
van Dijk EH; van Herpen CM; Marinkovic M; Haanen JB; Amundson D; Luyten GP; Jager MJ; Kapiteijn EH; Keunen JE; Adamus G; Boon CJ
Ophthalmology; 2015 Sep; 122(9):1907-16. PubMed ID: 26123090
[TBL] [Abstract][Full Text] [Related]
5. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
[TBL] [Abstract][Full Text] [Related]
6. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
7. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer.
McCannel TA; Chmielowski B; Finn RS; Goldman J; Ribas A; Wainberg ZA; McCannel CA
JAMA Ophthalmol; 2014 Aug; 132(8):1005-9. PubMed ID: 24852144
[TBL] [Abstract][Full Text] [Related]
8. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
9. Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Gavric AU; Ocvirk J; Mekjavic PJ
Radiol Oncol; 2018 Jun; 52(2):213-219. PubMed ID: 30018526
[TBL] [Abstract][Full Text] [Related]
10. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
Weber ML; Liang MC; Flaherty KT; Heier JS
JAMA Ophthalmol; 2016 Aug; 134(8):855-62. PubMed ID: 27309887
[TBL] [Abstract][Full Text] [Related]
11. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
12. A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.
Thomas CL; Mortimer PS; Larkin JM; Basu TN; Gore ME; Fearfield L
Clin Exp Dermatol; 2016 Apr; 41(3):267-71. PubMed ID: 26411345
[TBL] [Abstract][Full Text] [Related]
13. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
14. [Protein kinase inhibitors can induce retinopathy].
Lindboe JB; Ahmed HJ; Christakopoulos CE
Ugeskr Laeger; 2020 Aug; 182(32):. PubMed ID: 32800052
[TBL] [Abstract][Full Text] [Related]
15. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.
Duncan KE; Chang LY; Patronas M
Eye (Lond); 2015 Aug; 29(8):1003-12. PubMed ID: 26043707
[TBL] [Abstract][Full Text] [Related]
18. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.
Guedj M; Quéant A; Funck-Brentano E; Kramkimel N; Lellouch J; Monnet D; Longvert C; Gantzer A; Brézin AP
JAMA Ophthalmol; 2014 Dec; 132(12):1421-5. PubMed ID: 25125216
[TBL] [Abstract][Full Text] [Related]
19. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.
Jeng-Miller KW; Miller MA; Heier JS
Oncologist; 2024 May; 29(5):e616-e621. PubMed ID: 38527005
[TBL] [Abstract][Full Text] [Related]
20. Retinal toxicities of systemic anticancer drugs.
Arora S; Surakiatchanukul T; Arora T; Errera MH; Agrawal H; Lupidi M; Chhablani J
Surv Ophthalmol; 2022; 67(1):97-148. PubMed ID: 34048859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
